Get the Stockscreener App
4.25
9.25%
+0.36
After Hours:
4.317
0.067
+1.58%
Sutro Biopharma Inc stock is currently priced at $4.25, with a 24-hour trading volume of 570.44K.
It has seen a +9.25% increased in the last 24 hours and a -12.91% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $3.90 pivot point. If it approaches the $4.08 resistance level, significant changes may occur.
Previous Close:
$3.89
Open:
$3.9
24h Volume:
570.44K
Market Cap:
$347.50M
Revenue:
$153.73M
Net Income/Loss:
$-106.79M
P/E Ratio:
-1.7206
EPS:
-2.47
Net Cash Flow:
$-115.93M
1W Performance:
+25.18%
1M Performance:
-12.91%
6M Performance:
+62.21%
1Y Performance:
-22.45%
1D Range:
$3.895
$4.25
52W Range:
$2.005
$6.13
Sutro Biopharma Inc Stock (STRO) Company Profile
Name
Sutro Biopharma Inc
Sector
Industry
Phone
650-392-8412
Address
310 Utah Avenue, Suite 150, South San Francisco, CA
Sutro Biopharma Inc Stock (STRO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jun-18-21 | Initiated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-02-20 | Initiated | Jefferies | Buy |
| Jul-16-20 | Initiated | Wells Fargo | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Oct-07-19 | Initiated | BTIG Research | Buy |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Apr-29-19 | Initiated | H.C. Wainwright | Buy |
| Oct-22-18 | Initiated | JMP Securities | Mkt Outperform |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
| Oct-22-18 | Initiated | Wedbush | Outperform |
View All
Sutro Biopharma Inc Stock (STRO) Latest News
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock?
Zacks Investment Research
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
GlobeNewswire Inc.
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Benzinga
Navigating 4 Analyst Ratings For Sutro Biopharma
Benzinga
Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Sutro Biopharma Inc Stock (STRO) Financials Data
Sutro Biopharma Inc (STRO) Revenue 2024
STRO reported a revenue (TTM) of $153.73 million for the quarter ending December 31, 2023, a +126.84% rise year-over-year.
Sutro Biopharma Inc (STRO) Net Income 2024
STRO net income (TTM) was -$106.79 million for the quarter ending December 31, 2023, a +10.41% increase year-over-year.
Sutro Biopharma Inc (STRO) Cash Flow 2024
STRO recorded a free cash flow (TTM) of -$115.93 million for the quarter ending December 31, 2023, a -2,590% decrease year-over-year.
Sutro Biopharma Inc (STRO) Earnings per Share 2024
STRO earnings per share (TTM) was -$1.78 for the quarter ending December 31, 2023, a +24.89% growth year-over-year.
About Sutro Biopharma Inc
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis platform, XpressCF. The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for multiple myeloma and non-Hodgkin lymphoma; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers. It has collaboration and license agreement with Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused primarily on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
0.58%
1.18%
Cap:
|
Volume (24h):